Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	290
Overall Study	STARTED	Vilazodone 20 mg/Day	292
Overall Study	STARTED	Vilazodone 40 mg/Day	291
Overall Study	STARTED	Citalopram 40 mg/Day	289
Overall Study	Safety Population	Placebo	281
Overall Study	Safety Population	Vilazodone 20 mg/Day	288
Overall Study	Safety Population	Vilazodone 40 mg/Day	287
Overall Study	Safety Population	Citalopram 40 mg/Day	282
Overall Study	COMPLETED	Placebo	210
Overall Study	COMPLETED	Vilazodone 20 mg/Day	199
Overall Study	COMPLETED	Vilazodone 40 mg/Day	189
Overall Study	COMPLETED	Citalopram 40 mg/Day	200
Overall Study	NOT COMPLETED	Placebo	80
Overall Study	NOT COMPLETED	Vilazodone 20 mg/Day	93
Overall Study	NOT COMPLETED	Vilazodone 40 mg/Day	102
Overall Study	NOT COMPLETED	Citalopram 40 mg/Day	89

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01473381/flow